Insider Transactions in Q1 2023 at Bluebird Bio, Inc. (BLUE)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+28.62%
|
-
|
|
Mar 01
2023
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
67,600
+17.96%
|
-
|
|
Mar 01
2023
|
Richard A Colvin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+30.04%
|
-
|
|
Feb 01
2023
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 01
2023
|
Andrew Obenshain President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,420
-0.59%
|
$8,520
$6.38 P/Share
|
|
Feb 01
2023
|
Richard A Colvin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,153
-1.55%
|
$6,918
$6.38 P/Share
|
|
Feb 01
2023
|
Thomas J Klima |
SELL
Payment of exercise price or tax liability
|
Direct |
2,260
-2.68%
|
$13,560
$6.38 P/Share
|
|
Jan 11
2023
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
4,290
-1.51%
|
$30,030
$7.8 P/Share
|
|
Jan 11
2023
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
557
-0.74%
|
$3,899
$7.8 P/Share
|
|
Jan 11
2023
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
3,178
-1.29%
|
$22,246
$7.8 P/Share
|